Start of new trial of Tirzepatide in adolescent patients with obesity and weight-related comorbidities.
We are excited to announce that we have started treating adolescent patients (12-17 year-old) with obesity and associated weight-related health problems (hypertension, prediabetes and/or high triglycerides) with Tirzepatide, as part of the SURMOUNT-ADOLESCENTS-2 trial.
This trial follows on from the success of the previous SURMOUNT portfolio studies, where Tirzepatide has demonstrated major benefits in terms of weight loss and reduction of associated comorbidities in adult patients with obesity.
SURMOUNT-ADOLESCENTS-2 is a randomised, placebo-controlled, double-blind phase 3 trial sponsored by Lilly Pharmaceuticals that will be conducted across multiple centres around the world. Further details can be found here and here.